Boston Scientific cautious consensus picture, shares near 1-year low on NYSE

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-28, 15:05.

Boston Scientific (US10117L1017) sits in the S&P 500 with its BSX ticker on the NYSE, where the shares recently traded around 44 dollars per MarketBeat data as of June 26, 2026.MarketBeat price overview for Boston Scientific The focus today is on the cautious but broadly supportive analyst consensus that has formed after a string of recent updates.

What the analysts are saying

Over June, several research houses reiterated positive views on Boston Scientific, while acknowledging product headwinds and valuation questions.MarketScreener analyst summary for Boston Scientific MarketScreener lists recent notes from Stifel Nicolaus, Jefferies, Piper Sandler, Truist Securities, BTIG and TD Cowen, most of them on the Buy side, combined with one Neutral stance from BofA Securities as of mid-June 2026.

According to these updates, the Buy-rated houses broadly point to Boston Scientific’s pipeline in cardiology, electrophysiology and structural heart devices as key growth drivers, while BofA’s Neutral view highlights the balance between strong fundamentals and an already demanding valuation. The pattern offers a nuanced consensus picture rather than a one-sided bullish narrative.

Why the shares trade near a 1-year low

Despite the supportive research backdrop, Boston Scientific shares closed at 44.16 dollars on June 26, 2026, fractionally lower on the day and close to a new 1-year low, according to MarketBeat.MarketBeat quote and 52-week range for BSX MarketBeat highlights that BSX has recently reached this 1-year low level, flagging investor concerns around regulatory and litigation risks tied to certain devices.

One prominent operational issue has been Boston Scientific’s recall of sterile single-use Orca air/water and suction valves in the United States, which was reported earlier in June. Such quality and recall topics typically weigh on sentiment for medical device stocks, even when core growth metrics remain intact.

The products behind the stock

Boston Scientific generates most of its revenue from minimally invasive medical devices, including cardiac rhythm management systems, electrophysiology catheters, stents and structural heart products such as its Watchman left atrial appendage closure device. The company also sells devices for neuromodulation, urology and endoscopy, giving it a broad foothold across interventional specialties.

Where the shares trade today

The Boston Scientific shares (US10117L1017) last closed on the NYSE at 44.16 dollars on 2026-06-26, 15:59 Eastern Time, according to MarketBeat. That price leaves the company’s market cap in the mid double-digit billion-dollar range and close to its 1-year low.

Disclaimer: This article is for informational purposes only and does not constitute investment advice, a recommendation or an offer to buy or sell any financial instrument. All data are based on sources believed to be reliable but cannot be guaranteed. Investors should conduct their own research or consult a professional adviser before making investment decisions.